Chris Sheldon - AstraZeneca PLC Head Relations

All Insiders . USA . 
Stock . AstraZeneca PLC . Stakeholders . Insider . Chris Sheldon
AZNCF Stock  USD 138.10  4.00  2.98%   

Insider

Chris Sheldon is Head Relations of AstraZeneca PLC
Phone44 20 3749 5000
Webhttps://www.astrazeneca.com

AstraZeneca PLC Management Efficiency

The company has return on total asset (ROA) of 0.0531 % which means that it generated a profit of $0.0531 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0863 %, meaning that it generated $0.0863 on every $100 dollars invested by stockholders. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities.
AstraZeneca PLC has accumulated 22.96 B in total debt with debt to equity ratio (D/E) of 0.87, which is about average as compared to similar companies. AstraZeneca PLC has a current ratio of 0.94, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist AstraZeneca PLC until it has trouble settling it off, either with new capital or with free cash flow. So, AstraZeneca PLC's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like AstraZeneca PLC sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for AstraZeneca to invest in growth at high rates of return. When we think about AstraZeneca PLC's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Claudia BockstiegelRoche Holding AG
59
Claudia BockstiegelRoche Holding AG
59
Claudia BockstiegelRoche Holding Ltd
59
Maria LlanoGrifols SA ADR
59
Pascale SchmidtRoche Holding Ltd
50
Katsuyoshi SugitaAstellas Pharma
N/A
Robert PharmDNovartis AG
55
MarieFrance TschudinNovartis AG
52
Bruno MnardSanofi ADR
N/A
Richard SaynorNovartis AG
56
Rodrigo SantosBayer AG
50
Dante BeccariaSanofi ADR
N/A
Marielle MDDaiichi Sankyo
N/A
Catherine LevittAstellas Pharma
N/A
Sunao DVMDaiichi Sankyo
69
Junichi OnumaDaiichi Sankyo
N/A
Hideyuki HaruyamaDaiichi Sankyo
N/A
Katsuyoshi SugitaAstellas Pharma
N/A
Sarena LinBayer AG
52
Josephine FubaraSanofi ADR
N/A
Johannes MDRoche Holding AG
66
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Astrazeneca Plc operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 83100 people. AstraZeneca PLC [AZNCF] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

Return On Equity0.0863
Return On Asset0.0531

AstraZeneca PLC Leadership Team

Elected by the shareholders, the AstraZeneca PLC's board of directors comprises two types of representatives: AstraZeneca PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AstraZeneca. The board's role is to monitor AstraZeneca PLC's management team and ensure that shareholders' interests are well served. AstraZeneca PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AstraZeneca PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
Marc Dunoyer, CFO and Executive Director
Chris Sheldon, Head Relations
Pam Cheng, Executive Vice-President of Operations and Information Technology
MBA DVM, CEO Director
Gonzalo Vina, Head Relations
Aradhana MD, CFO Director
Menelas Pangalos, Executive Vice President - Innovative Medicines
Katarina Ageborg, Chief Compliance Officer
Jeffrey Pott, General Counsel
Ruud Dobber, Executive Vice President Europe

AstraZeneca Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is AstraZeneca PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.0863
Return On Asset0.0531
Profit Margin0.07 %
Operating Margin0.19 %
Current Valuation241.1 B
Shares Outstanding1.55 B
Shares Owned By Insiders0.22 %
Shares Owned By Institutions48.84 %
Price To Earning44.18 X
Price To Book6.16 X

Currently Active Assets on Macroaxis

CCitigroup
GMGeneral Motors
FFord Motor
GMGeneral Motors
VVisa Class A

Other Information on Investing in AstraZeneca Pink Sheet

AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY